Oral Tirzepatide FDA Status (2026): What's Approved, What's Compounded, and How PlexusDx Fits | PlexusDx

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you've searched “oral tirzepatide FDA approved” and gotten a wall of contradictory pages, here is the short version: as of April 2026, no oral tirzepatide product is FDA-approved as a finished branded drug. The only FDA-approved tirzepatide products are injectable Mounjaro (type 2 diabetes) and injectable Zepbound (chronic weight management), both administered as once-weekly subcutaneous injections by Eli Lilly. Anything labeled “oral tirzepatide,” “tirzepatide drops,” or “tirzepatide ODT” is a compounded preparation, not an FDA-approved finished drug. This guide walks the actual regulatory status, what compounded oral tirzepatide is and isn't, the safety considerations, and where the PlexusDx Tirzepatide Oral protocol ($279/mo) fits relative to the FDA-approved injectable options — because the “is there a tirzepatide pill?” question has a clearer answer once you separate FDA approval status from medication availability.

The FDA-approved tirzepatide products are both injectable

Eli Lilly's tirzepatide molecule has two FDA approvals, both for once-weekly subcutaneous injection. Mounjaro was approved in May 2022 for type 2 diabetes. Zepbound was approved in November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Both deliver tirzepatide, a dual GIP/GLP-1 receptor agonist, in a once-weekly pen or vial at doses from 2.5mg up to 15mg. Neither comes as a pill, tablet, capsule, lozenge, troche, or sublingual drop. Eli Lilly's medical information page is explicit: tirzepatide is not available in pill form for oral administration. If you want the FDA-approved finished branded product, it is an injection — full stop. PlexusDx Tirzepatide Injection ($249/mo) provides a compounded weekly injectable in the same active-ingredient family for cash-pay patients without insurance coverage for Zepbound or Mounjaro.

Is oral tirzepatide FDA approved? No — and here's why

As of April 2026, no oral tirzepatide is FDA-approved. Tirzepatide is a 39-amino-acid peptide, and like most peptides it is rapidly degraded by digestive enzymes when swallowed, so an oral formulation requires either a delivery technology that protects the peptide through the gut (the SNAC absorption enhancer used in Rybelsus and the Wegovy pill is the only such technology cleared in the GLP-1 space) or an alternate route such as sublingual that bypasses first-pass digestion. Eli Lilly has not announced an oral tirzepatide development program. Their oral GLP-1 candidate, orforglipron, is a small-molecule GLP-1 agonist — a different drug, not an oral version of tirzepatide. So the regulatory pipeline does not currently include an FDA-approved oral tirzepatide; the question “when will oral tirzepatide be approved?” has no public answer.

What compounded oral tirzepatide actually is

If oral tirzepatide isn't FDA-approved but you've seen it sold online — as drops, ODT (orally disintegrating tablets), capsules, or sublingual solutions — what you're looking at is a compounded preparation. Compounded medications are prepared by a licensed compounding pharmacy that combines or modifies ingredients to meet a specific patient's prescription. They are not FDA-approved finished drug products; they are pharmacy-prepared versions of the active ingredient operating under a different regulatory framework (state boards of pharmacy and federal compounding statutes rather than FDA new-drug approval). During the 2022–2024 tirzepatide shortage, compounded tirzepatide — injectable and various oral formats — was widely available under the FDA's enforcement discretion for shortage drugs. After the FDA declared the shortage resolved in late 2024 and enforcement wind-down dates passed in 2025, routine compounding of tirzepatide copies based on the shortage exception ended. Compounded tirzepatide can still be prepared in narrower patient-specific circumstances (for example, a documented clinical need that the commercial product cannot meet), and several telehealth platforms continue to dispense it through licensed compounding pharmacies operating within those exceptions.

How the PlexusDx Tirzepatide Oral protocol fits

PlexusDx Tirzepatide Oral ($279/mo) is a compounded oral GIP/GLP-1 dual-agonist protocol with seven dose levels from 5mg up to 25mg daily, prepared by licensed U.S. compounding pharmacies and prescribed through a licensed clinician after async or live intake. It is not an FDA-approved finished drug — we say that plainly because it matters. It is the same active ingredient family as the FDA-approved injectable Zepbound and Mounjaro, in a daily oral format, dispensed under the compounding-pharmacy regulatory framework rather than the FDA new-drug-approval framework. PlexusDx Weight Management Protocols are cash-pay (no insurance, no membership), available in all 50 states (five require a scheduled live consult rather than async intake), and the bill includes the clinician visit, prescription, compounded medication, and shipping in one all-inclusive monthly price. If you prefer the injectable route, Tirzepatide Injection ($249/mo) covers the same molecule at 2.5mg–15mg weekly. If you want a genetic baseline informing dose selection before titration, the Precision Peptide Genetic Test is $298 standalone or $99 as an add-on after your first month on any protocol — it maps 48 genes and 57 variants including GIPR rs1800437, the variant most associated with differential tirzepatide response.

Safety, side effects, and the boxed warning that applies to both

Whether tirzepatide is delivered as a weekly injection or a daily oral, the side-effect profile of the active ingredient is the same. Common: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache — usually worst during dose escalation and improving over the first 8–12 weeks. Less common but documented: pancreatitis, gallbladder disease, and acute kidney injury (often related to dehydration from GI side effects). The FDA boxed warning for thyroid C-cell tumors applies to tirzepatide based on rodent studies; tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The same boxed warning applies to semaglutide (Wegovy, Ozempic, Rybelsus). Compounded tirzepatide is not exempt from the underlying drug safety considerations — the active ingredient behaves the same way regardless of who prepared it. Discuss any GLP-1 medication decision with a licensed clinician, and report any concerning symptoms (severe abdominal pain, persistent vomiting, signs of pancreatitis or gallbladder disease) immediately.

Spotting unsafe “oral tirzepatide” products

Not every site selling something called “oral tirzepatide” is operating within a legitimate compounding framework. Red flags: products marketed “for research use only” or “not for human consumption” that nonetheless include human dosing instructions; sites that don't name the dispensing pharmacy or its licensure; products sold without a clinician evaluation or prescription; pricing that is dramatically lower than the compounding-pharmacy market norm; international suppliers shipping unapproved peptides into the U.S.; and any product that claims to be FDA-approved when no FDA-approved oral tirzepatide exists. The FDA's BeSafeRx program (FDA.gov/BeSafeRx) lets you verify whether an online pharmacy is licensed in the state where it claims to operate. PlexusDx works only with licensed U.S. compounding pharmacies and a licensed clinical team; pricing is published on every product page; the medication source is disclosed.

Frequently asked questions

Is oral tirzepatide FDA approved?

No. As of April 2026, no oral tirzepatide product is FDA-approved as a finished branded drug. The only FDA-approved tirzepatide products are injectable Mounjaro (diabetes) and injectable Zepbound (weight management), both from Eli Lilly.

Is there a tirzepatide pill from a brand-name manufacturer?

No. Eli Lilly has not announced an oral tirzepatide development program. Their oral GLP-1 candidate orforglipron is a different drug (a small-molecule GLP-1 agonist), not an oral version of tirzepatide.

What is compounded oral tirzepatide, and is PlexusDx Tirzepatide Oral one of them?

Compounded oral tirzepatide is a pharmacy-prepared formulation of the active ingredient, not an FDA-approved finished drug. PlexusDx Tirzepatide Oral ($279/mo, 5mg–25mg daily across seven dose levels) is a compounded oral GIP/GLP-1 dual-agonist prepared by licensed U.S. compounding pharmacies and prescribed through a licensed clinician.

Can I still get compounded oral tirzepatide after the shortage was declared resolved?

Routine shortage-era compounding of tirzepatide copies ended in 2025 after FDA enforcement wind-down dates passed. Compounded tirzepatide can still be prepared in narrower patient-specific circumstances under federal compounding statutes, and PlexusDx Tirzepatide Oral is dispensed within that framework through licensed U.S. compounding pharmacies.

Is oral tirzepatide as effective as injectable Zepbound?

There are no head-to-head clinical trials of oral tirzepatide versus injectable Zepbound because no oral tirzepatide is FDA-approved and no large randomized trial of compounded oral tirzepatide exists. Injectable tirzepatide produced 20–22% mean weight loss in the SURMOUNT trials. Oral formulations face peptide-absorption challenges that brand-name oral semaglutide products address with a dedicated absorption enhancer; compounded oral tirzepatide does not have that public clinical-trial data.

How much does PlexusDx Tirzepatide Oral cost?

PlexusDx Tirzepatide Oral is $279/mo across seven dose levels (5mg to 25mg daily), all-inclusive (clinician visit, prescription, compounded medication, and shipping). PlexusDx is cash-pay, no membership, available in all 50 states.

Should I get a genetic test before starting tirzepatide?

It's optional but useful if you've had inconsistent response to GLP-1 therapy or want a measurable baseline before titration. The Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) maps 48 genes and 57 variants, including GIPR rs1800437, the variant most associated with differential tirzepatide response.

Related reading on PlexusDx

Related reading on PlexusDx: Tirzepatide Costs, Oral Semaglutide, Compounded Tirzepatide, GLP-1 Cost.

Disclaimer: This article is educational and is not medical advice. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols. Information about Mounjaro, Zepbound, and FDA regulatory status is based on publicly available FDA records and Eli Lilly disclosures as of April 2026; actual costs and availability may vary by state, plan, and individual eligibility. PlexusDx does not sell, prescribe, or recommend any therapeutic peptide outside the GLP-1 category covered by its protocols. Discuss any GLP-1 medication decision with a licensed clinician.